Aquilo Capital Management, LLC
SAN FRANCISCO, CA · CIK 1591986 · 13F filing filed 2020-08-14
No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.
- Legal entityAQUILO CAPITAL MANAGEMENT, LLC (US)
- Others nearbySan Francisco, CA
$272.0m
reported value
+51.8% vs Q1 2020
13positions
92.7%in top 10
2 new
7 added
0 reduced
2 sold out
vs Q1 2020
Options: 0 call positions (— notional), 1 put positions ($223.9m notional) – listed below, not included above.
Holdings, Q2 2020
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| DICERNA PHARMACEUTICALS INC DRNA | $36.9m13.58% | Added +217.3k |
| ANAPTYSBIO INC ANAB | $35.5m13.06% | Added +151.7k |
| UNIQURE NV QURE | $30.6m11.26% | Added +177.6k |
| SPERO THERAPEUTICS INC SPRO | $26.3m9.66% | Added +124.9k |
| BLUEPRINT MEDICINES CORP BPMC | $24.6m9.03% | New |
| ARROWHEAD PHARMACEUTICALS IN ARWR | $24.3m8.94% | Added +126.8k |
| NGM BIOPHARMACEUTICALS INC NGM | $21.6m7.95% | Added +48.0k |
| REGENXBIO INC RGNX | $20.4m7.49% | Added +280.2k |
| PIERIS PHARMACEUTICALS INC COM | $17.3m6.35% | Unchanged |
| PROQR THRAPEUTICS N V PRQR | $14.6m5.37% | Unchanged |
| GALAPAGOS NV LKFT | $8.7m3.21% | Unchanged |
| ARGENX SE ARGX | $8.1m2.96% | New |
| MORPHOSYS AG SPONSORED ADS | $3.0m1.12% | Unchanged |
Sold out since Q1 2020
| Security | Value then |
|---|---|
| XENON PHARMACEUTICALS INC XENE | $17.0m1.5m shares |
| MERUS N V MRUS | $9.3m770.2k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| SPDR SER TR XBI · Put | $223.9m2.0m shares | Added |